title: Tolerance to etoricoxib in 37 patients with urticaria and angioedema induced by nonsteroidal anti-inflammatory drugs.
abstract: BACKGROUND
  The use of cyclooxygenase-2 inhibitors, a new class of analgesic drugs, is suggested in patients with hypersensitivity to nonsteroidal anti-inflammatory drugs (NSAIDs).
  
  
  OBJECTIVE
  To evaluate tolerance to etoricoxib, a new cyclooxygenase-2 inhibitor, in NSAID-sensitive patients with urticaria-type adverse reactions.
  
  
  METHODS
  Thirty-seven patients with adverse reactions to NSAIDs.
  
  
  METHODS
  Single-blind, placebo-controlled oral challenge with increasing doses of etoricoxib.
  
  
  RESULTS
  Thirty-four patients tolerated etoricoxib treatment without adverse reactions, but a generalized urticarial rash developed in 3 patients (8%).
  
  
  CONCLUSIONS
  Etoricoxib, like other cyclooxygenase-2 inhibitors, is a well-tolerated drug in most NSAID-sensitive patients. However, according to our experience, a previous challenge test in a safe environment may be necessary before prescribing the drug to such patients.
authors.affiliation: Allergology and Clinical Immunology Service, Vito Fazzi Hospital, Lecce, Italy.
authors.forename: Lionello
authors.initials: L
authors.lastname: Muratore
authors.forename: Mariateresa
authors.initials: M
authors.lastname: Ventura
authors.forename: Gianfranco
authors.initials: G
authors.lastname: Calogiuri
authors.forename: Fabio
authors.initials: F
authors.lastname: Calcagnile
authors.forename: Eugenio
authors.initials: E
authors.lastname: Quarta
authors.forename: Maurizio
authors.initials: M
authors.lastname: Muratore
authors.forename: Antonio
authors.initials: A
authors.lastname: Ferrannini
mesh_terms: D000328:Adult; D000799:Angioedema / Q000139:chemically induced; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D001241:Aspirin / Q000009:adverse effects; D001794:Blood Pressure; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D004342:Drug Hypersensitivity / Q000209:etiology; D000077613:Etoricoxib; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010366:Peak Expiratory Flow Rate; D011725:Pyridines / Q000009:adverse effects*; D013450:Sulfones / Q000009:adverse effects*; D014581:Urticaria / Q000139:chemically induced
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D052246:Cyclooxygenase 2 Inhibitors; D011725:Pyridines; D013450:Sulfones; D001241:Aspirin; D000077613:Etoricoxib